JP2016513135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513135A5 JP2016513135A5 JP2015560105A JP2015560105A JP2016513135A5 JP 2016513135 A5 JP2016513135 A5 JP 2016513135A5 JP 2015560105 A JP2015560105 A JP 2015560105A JP 2015560105 A JP2015560105 A JP 2015560105A JP 2016513135 A5 JP2016513135 A5 JP 2016513135A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- methyl
- dihydro
- phenyl
- dibenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 92
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 52
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 40
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- -1 hydroxy, amino Chemical group 0.000 claims 31
- 125000003545 alkoxy group Chemical group 0.000 claims 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 29
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000004452 carbocyclyl group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000002252 acyl group Chemical group 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- VTZDPQGGOUEESD-UHFFFAOYSA-N 4-hexynoic acid Chemical compound CC#CCCC(O)=O VTZDPQGGOUEESD-UHFFFAOYSA-N 0.000 claims 9
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000004323 oxepin-2-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C(*)O1 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 5
- ZAWLXPIBKBSORZ-JOCHJYFZSA-N 2-[(3s)-6-[[11-methyl-9-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzoxepin-4-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=CC=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3CCOC2=C1COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 ZAWLXPIBKBSORZ-JOCHJYFZSA-N 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000010444 Acidosis Diseases 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000007976 Ketosis Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 206010049088 Osteopenia Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010047571 Visual impairment Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000007950 acidosis Effects 0.000 claims 2
- 208000026545 acidosis disease Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 150000004303 annulenes Chemical class 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010022498 insulinoma Diseases 0.000 claims 2
- 230000004140 ketosis Effects 0.000 claims 2
- 230000000512 lipotoxic effect Effects 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- 208000017443 reproductive system disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000029257 vision disease Diseases 0.000 claims 2
- 230000004393 visual impairment Effects 0.000 claims 2
- QWKFHQBHGGWTKX-IZZNHLLZSA-N (1R,2R)-2-[4-[[10-methyl-8-(3-methylsulfonylpropoxy)-6H-benzo[c]chromen-4-yl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC1=CC(=CC=2COC3=C(C=CC=C3C=21)CNC1=CC=C(C=C1)[C@H]1[C@@H](C1)C(=O)O)OCCCS(=O)(=O)C QWKFHQBHGGWTKX-IZZNHLLZSA-N 0.000 claims 1
- ZXRZZQNOFMDGER-NOZRDPDXSA-N (1S,2S)-2-[4-[(3-methyl-5-morpholin-4-yl-4,6-diazatricyclo[9.4.0.02,7]pentadeca-1(11),2,4,6,12,14-hexaen-14-yl)methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC1=C2C(=NC(=N1)N1CCOCC1)CCCC1=C2C=C(C=C1)COC1=CC=C(C=C1)[C@@H]1[C@H](C1)C(=O)O ZXRZZQNOFMDGER-NOZRDPDXSA-N 0.000 claims 1
- UZNIRXPXTOGJRM-IHLOFXLRSA-N (1S,2S)-2-[4-[[13-(3-ethylsulfonylpropoxy)-4-tricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaenyl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound C(C)S(=O)(=O)CCCOC1=CC2=C(C3=C(CCC2)C=CC(=C3)CNC3=CC=C(C=C3)[C@@H]3[C@H](C3)C(=O)O)C=C1 UZNIRXPXTOGJRM-IHLOFXLRSA-N 0.000 claims 1
- BBOZFFRFDZWJKG-WDYNHAJCSA-N (1S,2S)-2-[4-[[13-(3-methylsulfonylpropoxy)-4-tricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaenyl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound CS(=O)(=O)CCCOC1=CC2=C(C3=C(CCC2)C=CC(=C3)CNC3=CC=C(C=C3)[C@@H]3[C@H](C3)C(=O)O)C=C1 BBOZFFRFDZWJKG-WDYNHAJCSA-N 0.000 claims 1
- XYGJZJFYTQZECR-PXJZQJOASA-N (1S,2S)-2-[4-[[5-ethyl-9-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzazepin-2-yl]methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound C(C)N1C2=C(C3=C(CC1)C=C(C=C3)OCCCS(=O)(=O)C)C=C(C=C2)COC2=CC=C(C=C2)[C@@H]2[C@H](C2)C(=O)O XYGJZJFYTQZECR-PXJZQJOASA-N 0.000 claims 1
- SRWGXOCQXSLXIY-VPUSJEBWSA-N (1S,2S)-2-[4-[[9-(2-ethoxyethoxy)-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound C(C)OCCOC1=CC2=C(C3=C(OCC2)C=CC(=C3)CNC3=CC=C(C=C3)[C@@H]3[C@H](C3)C(=O)O)C=C1 SRWGXOCQXSLXIY-VPUSJEBWSA-N 0.000 claims 1
- YLGDCKPEOLQJFT-FTJBHMTQSA-N (1S,2S)-2-[4-[[9-(3-ethylsulfonylpropoxy)-11-methyl-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methoxy]-2-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound C(C)S(=O)(=O)CCCOC1=CC2=C(C3=C(OCC2)C=CC(=C3)COC3=CC(=C(C=C3)[C@@H]3[C@H](C3)C(=O)O)F)C(=C1)C YLGDCKPEOLQJFT-FTJBHMTQSA-N 0.000 claims 1
- VLCZMSUIFYTVHK-VPUSJEBWSA-N (1S,2S)-2-[4-[[9-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound CS(=O)(=O)CCCOC1=CC2=C(C3=C(OCC2)C=CC(=C3)COC3=CC=C(C=C3)[C@@H]3[C@H](C3)C(=O)O)C=C1 VLCZMSUIFYTVHK-VPUSJEBWSA-N 0.000 claims 1
- VFBVSVRCAJBJKR-VPUSJEBWSA-N (1S,2S)-2-[4-[[9-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound CS(=O)(=O)CCCOC1=CC2=C(C3=C(OCC2)C=CC(=C3)CNC3=CC=C(C=C3)[C@@H]3[C@H](C3)C(=O)O)C=C1 VFBVSVRCAJBJKR-VPUSJEBWSA-N 0.000 claims 1
- FTNHPSKGTRCBES-RPBOFIJWSA-N (1s,2s)-2-[4-[[10-methyl-8-(3-methylsulfonylpropoxy)-6h-benzo[c]chromen-2-yl]methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound C1=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3COC2=CC=C1COC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O FTNHPSKGTRCBES-RPBOFIJWSA-N 0.000 claims 1
- RBCAFEQTCYGZJN-RPBOFIJWSA-N (1s,2s)-2-[4-[[10-methyl-8-(3-methylsulfonylpropoxy)-6h-benzo[c]chromen-2-yl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound C1=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3COC2=CC=C1CNC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O RBCAFEQTCYGZJN-RPBOFIJWSA-N 0.000 claims 1
- UAVADONVEHUQBW-FTJBHMTQSA-N (1s,2s)-2-[4-[[11-methyl-9-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound C1=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3CCOC2=CC=C1COC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O UAVADONVEHUQBW-FTJBHMTQSA-N 0.000 claims 1
- RNUXLXCFOCANHO-IZLXSDGUSA-N (1s,2s)-2-[4-[[3-(2-ethoxyethoxy)-5,7-dihydrobenzo[d][2]benzoxepin-10-yl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C(OCCOCC)=CC=C(C2=C3)C=1COCC2=CC=C3CNC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O RNUXLXCFOCANHO-IZLXSDGUSA-N 0.000 claims 1
- KBFHYWVNASLSDY-DGPALRBDSA-N (1s,2s)-2-[4-[[3-(3-ethylsulfonylpropoxy)-1-methyl-6,7-dihydro-5h-dibenzo[1,3-a:1',3'-d][7]annulen-10-yl]methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C(OCCCS(=O)(=O)CC)=CC(C)=C(C2=C3)C=1CCCC2=CC=C3COC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O KBFHYWVNASLSDY-DGPALRBDSA-N 0.000 claims 1
- YPOMXZKYMWUDBI-IZLXSDGUSA-N (1s,2s)-2-[4-[[3-(3-methylsulfonylpropoxy)-5,7-dihydrobenzo[d][2]benzoxepin-10-yl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C(OCCCS(=O)(=O)C)=CC=C(C2=C3)C=1COCC2=CC=C3CNC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O YPOMXZKYMWUDBI-IZLXSDGUSA-N 0.000 claims 1
- RSCJIQIRRUWLCA-SXOMAYOGSA-N (1s,2s)-2-[4-[[3-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzoxepin-10-yl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C(OCCCS(=O)(=O)C)=CC=C(C2=C3)C=1OCCC2=CC=C3CNC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O RSCJIQIRRUWLCA-SXOMAYOGSA-N 0.000 claims 1
- YMTDLLHKQFSZBG-IAPPQJPRSA-N (1s,2s)-2-[4-[[5-methyl-7-(3-methylsulfonylpropoxy)-9,10-dihydrophenanthren-3-yl]methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound C1=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3CCC2=CC=C1COC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O YMTDLLHKQFSZBG-IAPPQJPRSA-N 0.000 claims 1
- JNHPWWJYPADQAM-RPBOFIJWSA-N (1s,2s)-2-[4-[[8-(2-ethoxyethoxy)-10-methyl-6h-benzo[c]chromen-2-yl]methylamino]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C(OCCOCC)=CC(C)=C(C2=C3)C=1COC2=CC=C3CNC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O JNHPWWJYPADQAM-RPBOFIJWSA-N 0.000 claims 1
- YCUCEICXEVBLIV-SXOMAYOGSA-N (1s,2s)-2-[4-[[9-(3-ethylsulfonylpropoxy)-11-methyl-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C(OCCCS(=O)(=O)CC)=CC(C)=C(C2=C3)C=1CCOC2=CC=C3COC(C=C1)=CC=C1[C@H]1C[C@@H]1C(O)=O YCUCEICXEVBLIV-SXOMAYOGSA-N 0.000 claims 1
- RKMRQTMCXUOJRM-SANMLTNESA-N (3S)-3-[4-[[13-(3-methylsulfonylpropoxy)-4-tricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaenyl]methoxy]phenyl]hex-4-ynoic acid Chemical compound CS(=O)(=O)CCCOC1=CC2=C(C3=C(CCC2)C=CC(=C3)COC3=CC=C(C=C3)[C@H](CC(=O)O)C#CC)C=C1 RKMRQTMCXUOJRM-SANMLTNESA-N 0.000 claims 1
- LEWAITPXKDMFDL-SANMLTNESA-N (3S)-3-[4-[[13-(3-methylsulfonylpropoxy)-4-tricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaenyl]methylamino]phenyl]hex-4-ynoic acid Chemical compound CS(=O)(=O)CCCOC1=CC2=C(C3=C(CCC2)C=CC(=C3)CNC3=CC=C(C=C3)[C@H](CC(=O)O)C#CC)C=C1 LEWAITPXKDMFDL-SANMLTNESA-N 0.000 claims 1
- LQBOJUSLNBXXFZ-MHZLTWQESA-N (3S)-3-[4-[[15-methyl-13-(3-methylsulfonylpropoxy)-4-tricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaenyl]methoxy]phenyl]hex-4-ynoic acid Chemical compound CC1=CC(=CC2=C1C1=C(CCC2)C=CC(=C1)COC1=CC=C(C=C1)[C@H](CC(=O)O)C#CC)OCCCS(=O)(=O)C LQBOJUSLNBXXFZ-MHZLTWQESA-N 0.000 claims 1
- BQJPAPVGKLJRFA-LITSAYRRSA-N (3S)-3-[4-[[15-methyl-13-[(3R)-oxolan-3-yl]oxy-4-tricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaenyl]methoxy]phenyl]hex-4-ynoic acid Chemical compound CC1=CC(=CC2=C1C1=C(CCC2)C=CC(=C1)COC1=CC=C(C=C1)[C@H](CC(=O)O)C#CC)O[C@H]1COCC1 BQJPAPVGKLJRFA-LITSAYRRSA-N 0.000 claims 1
- NZKPGFORNZSLOL-VWLOTQADSA-N (3S)-3-[4-[[3-methyl-5-(3-methylsulfonylpropoxy)-4,6-diazatricyclo[9.4.0.02,7]pentadeca-1(11),2,4,6,12,14-hexaen-14-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound CC1=C2C(=NC(=N1)OCCCS(=O)(=O)C)CCCC1=C2C=C(C=C1)COC1=CC=C(C=C1)[C@H](CC(=O)O)C#CC NZKPGFORNZSLOL-VWLOTQADSA-N 0.000 claims 1
- OSIVDCAGXJSMRC-SANMLTNESA-N (3S)-3-[4-[[5-(3-ethylsulfonylpropoxy)-6-azatricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaen-14-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C(C)S(=O)(=O)CCCOC1=CC=C2C(=N1)CCCC1=C2C=C(C=C1)COC1=CC=C(C=C1)[C@H](CC(=O)O)C#CC OSIVDCAGXJSMRC-SANMLTNESA-N 0.000 claims 1
- JXKPFSTWHVWGBY-VWLOTQADSA-N (3S)-3-[4-[[5-(3-methylsulfonylpropoxy)-6-azatricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaen-14-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound CS(=O)(=O)CCCOC1=CC=C2C(=N1)CCCC1=C2C=C(C=C1)COC1=CC=C(C=C1)[C@H](CC(=O)O)C#CC JXKPFSTWHVWGBY-VWLOTQADSA-N 0.000 claims 1
- UAJIMIBESMZHGC-VWLOTQADSA-N (3S)-3-[4-[[6,6-dimethyl-9-(3-methylsulfonylpropoxy)-7H-benzo[d][1]benzoxepin-2-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound CC1(CC2=C(C3=C(O1)C=CC(=C3)COC3=CC=C(C=C3)[C@H](CC(=O)O)C#CC)C=CC(=C2)OCCCS(=O)(=O)C)C UAJIMIBESMZHGC-VWLOTQADSA-N 0.000 claims 1
- KYBSQIFXFHONSB-SANMLTNESA-N (3S)-3-[4-[[7-(2-ethoxyethoxy)-5-methyl-9,10-dihydrophenanthren-3-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C(C)OCCOC1=CC(=C2C=3C=C(C=CC3CCC2=C1)COC1=CC=C(C=C1)[C@H](CC(=O)O)C#CC)C KYBSQIFXFHONSB-SANMLTNESA-N 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 claims 1
- CFEYXNHWGYKPAN-OAQYLSRUSA-N 2-[(3S)-6-[(3-methyl-5-morpholin-4-yl-4,6-diazatricyclo[9.4.0.02,7]pentadeca-1(11),2,4,6,12,14-hexaen-14-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CC1=C2C(=NC(=N1)N1CCOCC1)CCCC1=C2C=C(C=C1)COC1=CC2=C([C@@H](CO2)CC(=O)O)C=C1 CFEYXNHWGYKPAN-OAQYLSRUSA-N 0.000 claims 1
- DIZDRDQFMBSVFK-JOCHJYFZSA-N 2-[(3S)-6-[[3-(2-ethoxyethoxy)-5,7-dihydrobenzo[d][2]benzoxepin-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C(C)OCCOC1=CC2=C(C3=C(COC2)C=CC(=C3)COC2=CC3=C([C@@H](CO3)CC(=O)O)C=C2)C=C1 DIZDRDQFMBSVFK-JOCHJYFZSA-N 0.000 claims 1
- IQPZUBVNLVDCJC-JOCHJYFZSA-N 2-[(3S)-6-[[3-(3-methylsulfonylpropoxy)-5,7-dihydrobenzo[d][2]benzoxepin-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CS(=O)(=O)CCCOC1=CC2=C(C3=C(COC2)C=CC(=C3)COC3=CC2=C([C@@H](CO2)CC(=O)O)C=C3)C=C1 IQPZUBVNLVDCJC-JOCHJYFZSA-N 0.000 claims 1
- AONCEYVIAOKSAH-OAQYLSRUSA-N 2-[(3S)-6-[[3-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzoxepin-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CS(=O)(=O)CCCOC=1C=CC2=C(OCCC3=C2C=C(C=C3)COC3=CC2=C([C@@H](CO2)CC(=O)O)C=C3)C1 AONCEYVIAOKSAH-OAQYLSRUSA-N 0.000 claims 1
- NFNZPZSQYYAYQH-LJQANCHMSA-N 2-[(3S)-6-[[3-(3-methylsulfonylpropoxy)benzo[d][1,3]benzodioxepin-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CS(=O)(=O)CCCOC1=CC2=C(C3=C(OCO2)C=CC(=C3)COC2=CC3=C([C@@H](CO3)CC(=O)O)C=C2)C=C1 NFNZPZSQYYAYQH-LJQANCHMSA-N 0.000 claims 1
- UABZXOHSISTHJY-HSZRJFAPSA-N 2-[(3S)-6-[[5-methyl-7-(3-methylsulfonylpropoxy)-9,10-dihydrophenanthren-3-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CC1=C2C=3C=C(C=CC3CCC2=CC(=C1)OCCCS(=O)(=O)C)COC1=CC2=C([C@@H](CO2)CC(=O)O)C=C1 UABZXOHSISTHJY-HSZRJFAPSA-N 0.000 claims 1
- JEICBCVITKTKER-JOCHJYFZSA-N 2-[(3S)-6-[[6,6-dimethyl-9-(3-methylsulfonylpropoxy)-7H-benzo[d][1]benzoxepin-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CC1(CC2=C(C3=C(O1)C=CC(=C3)COC3=CC1=C([C@@H](CO1)CC(=O)O)C=C3)C=CC(=C2)OCCCS(=O)(=O)C)C JEICBCVITKTKER-JOCHJYFZSA-N 0.000 claims 1
- FHALSIDSDYBJCO-HSZRJFAPSA-N 2-[(3S)-6-[[7-(2-ethoxyethoxy)-5-methyl-9,10-dihydrophenanthren-3-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CCOCCOC1=CC(C)=C2C(CCC3=C2C=C(COC2=CC4=C(C=C2)[C@H](CC(O)=O)CO4)C=C3)=C1 FHALSIDSDYBJCO-HSZRJFAPSA-N 0.000 claims 1
- CHVDQJTUOOFUOS-JOCHJYFZSA-N 2-[(3s)-6-[[1-methyl-3-(3-methylsulfonylpropoxy)-5,7-dihydrobenzo[d][2]benzoxepin-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3COCC2=CC=C1COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 CHVDQJTUOOFUOS-JOCHJYFZSA-N 0.000 claims 1
- SGBNKEBLLHAQDW-OAQYLSRUSA-N 2-[(3s)-6-[[1-methyl-3-(3-methylsulfonylpropoxy)-6,7-dihydro-5h-benzo[4,5]cyclohepta[1,2-d]pyrimidin-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=C2C=3C(C)=NC(OCCCS(C)(=O)=O)=NC=3CCCC2=CC=C1COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 SGBNKEBLLHAQDW-OAQYLSRUSA-N 0.000 claims 1
- OGWKGIFSRMGHFB-HSZRJFAPSA-N 2-[(3s)-6-[[1-methyl-3-(3-methylsulfonylpropoxy)-6,7-dihydro-5h-dibenzo[1,3-c:3',1'-g][7]annulen-8-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=CC=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3CCCC2=C1COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 OGWKGIFSRMGHFB-HSZRJFAPSA-N 0.000 claims 1
- QGGXCKUJHCKJBI-XMMPIXPASA-N 2-[(3s)-6-[[1-methyl-3-(3-methylsulfonylpropoxy)-6,7-dihydro-5h-dibenzo[1,3-d:1',3'-g][7]annulen-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3CCCC2=CC=C1COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 QGGXCKUJHCKJBI-XMMPIXPASA-N 0.000 claims 1
- JMDGZXNODYUKJA-HXUWFJFHSA-N 2-[(3s)-6-[[10-methyl-8-(3-methylsulfonylpropoxy)-6h-benzo[c]chromen-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=C2[C@H](CC(O)=O)COC2=CC(OCC2=CC=C3OCC=4C=C(OCCCS(C)(=O)=O)C=C(C=4C3=C2)C)=C1 JMDGZXNODYUKJA-HXUWFJFHSA-N 0.000 claims 1
- NRMMLXDUOGGYPX-JOCHJYFZSA-N 2-[(3s)-6-[[11-methyl-9-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=C2C=3C(C)=CC(OCCCS(C)(=O)=O)=CC=3CCOC2=CC=C1COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 NRMMLXDUOGGYPX-JOCHJYFZSA-N 0.000 claims 1
- WXWPSTWLLGSKQG-XMMPIXPASA-N 2-[(3s)-6-[[3-(2-ethoxyethoxy)-1-methyl-6,7-dihydro-5h-dibenzo[1,3-a:1',3'-d][7]annulen-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C(OCCOCC)=CC(C)=C(C2=C3)C=1CCCC2=CC=C3COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 WXWPSTWLLGSKQG-XMMPIXPASA-N 0.000 claims 1
- QWZFGUIHCGIENE-HSZRJFAPSA-N 2-[(3s)-6-[[3-(2-ethoxyethoxy)-6,7-dihydro-5h-dibenzo[3,1-d:3',1'-f][7]annulen-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C(OCCOCC)=CC=C(C2=C3)C=1CCCC2=CC=C3COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 QWZFGUIHCGIENE-HSZRJFAPSA-N 0.000 claims 1
- QLUNPCXDMXTHMX-RUZDIDTESA-N 2-[(3s)-6-[[3-(3-ethylsulfonylpropoxy)-1-methyl-6,7-dihydro-5h-dibenzo[1,3-a:1',3'-d][7]annulen-10-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C(OCCCS(=O)(=O)CC)=CC(C)=C(C2=C3)C=1CCCC2=CC=C3COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 QLUNPCXDMXTHMX-RUZDIDTESA-N 0.000 claims 1
- PSQDSVFJOIJRQM-HSZRJFAPSA-N 2-[(3s)-6-[[3-fluoro-9-(2-morpholin-4-ylethoxy)-6,7-dihydro-5h-dibenzo[4,3-b:3',1'-e][7]annulen-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C([C@H](C1=CC=2)CC(=O)O)OC1=CC=2OCC(C(=C1)F)=CC(C2=CC=3)=C1CCCC2=CC=3OCCN1CCOCC1 PSQDSVFJOIJRQM-HSZRJFAPSA-N 0.000 claims 1
- YGTIDXZAEKNOHN-OAQYLSRUSA-N 2-[(3s)-6-[[3-fluoro-9-(3-methylsulfonylpropoxy)-6,7-dihydro-5h-dibenzo[4,3-b:3',1'-e][7]annulen-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C(OCCCS(=O)(=O)C)=CC=C(C2=C3)C=1CCCC2=CC(F)=C3COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 YGTIDXZAEKNOHN-OAQYLSRUSA-N 0.000 claims 1
- YQSHYBNOSHXHPS-HYBUGGRVSA-N 2-[(3s)-6-[[3-fluoro-9-[(3r)-oxolan-3-yl]oxy-6,7-dihydro-5h-dibenzo[3,4-a:3',1'-c][7]annulen-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C([C@H](C1=CC=2)CC(=O)O)OC1=CC=2OCC(C(=C1)F)=CC(C2=CC=3)=C1CCCC2=CC=3O[C@@H]1CCOC1 YQSHYBNOSHXHPS-HYBUGGRVSA-N 0.000 claims 1
- CXRACAVAWUNNHW-JOCHJYFZSA-N 2-[(3s)-6-[[5-methyl-7-(3-methylsulfonylpropoxy)-9,10-dihydrophenanthren-1-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=C2[C@H](CC(O)=O)COC2=CC(OCC2=C3CCC=4C=C(OCCCS(C)(=O)=O)C=C(C=4C3=CC=C2)C)=C1 CXRACAVAWUNNHW-JOCHJYFZSA-N 0.000 claims 1
- XDQMAUSWXNPZBT-HXUWFJFHSA-N 2-[(3s)-6-[[8-(2-ethoxyethoxy)-10-methyl-6h-benzo[c]chromen-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=C2[C@H](CC(O)=O)COC2=CC(OCC2=CC=C3OCC=4C(C3=C2)=C(C)C=C(C=4)OCCOCC)=C1 XDQMAUSWXNPZBT-HXUWFJFHSA-N 0.000 claims 1
- XXHAAHYYRJTNES-JOCHJYFZSA-N 2-[(3s)-6-[[9-(2-ethoxyethoxy)-11-methyl-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C(OCCOCC)=CC(C)=C(C2=C3)C=1CCOC2=CC=C3COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 XXHAAHYYRJTNES-JOCHJYFZSA-N 0.000 claims 1
- MOAZPCNVWQGUFC-HSZRJFAPSA-N 2-[(3s)-6-[[9-(3-ethylsulfonylpropoxy)-11-methyl-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C(OCCCS(=O)(=O)CC)=CC(C)=C(C2=C3)C=1CCOC2=CC=C3COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 MOAZPCNVWQGUFC-HSZRJFAPSA-N 0.000 claims 1
- SRJBVWQYRMQPSB-JOCHJYFZSA-N 2-[(3s)-6-[[9-(3-ethylsulfonylpropoxy)-3-fluoro-6,7-dihydro-5h-dibenzo[4,3-b:3',1'-e][7]annulen-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C(OCCCS(=O)(=O)CC)=CC=C(C2=C3)C=1CCCC2=CC(F)=C3COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 SRJBVWQYRMQPSB-JOCHJYFZSA-N 0.000 claims 1
- KPVSGHMBTLTZMS-OAQYLSRUSA-N 2-[(3s)-6-[[9-(3-methylsulfonylpropoxy)-6,7-dihydrobenzo[d][1]benzoxepin-2-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C(OCCCS(=O)(=O)C)=CC=C(C2=C3)C=1CCOC2=CC=C3COC1=CC=C([C@H](CC(O)=O)CO2)C2=C1 KPVSGHMBTLTZMS-OAQYLSRUSA-N 0.000 claims 1
- HLILQLUWVHRVRM-RUZDIDTESA-N CC1=C2C=3C=C(C=CC3CCC2=CC(=C1)OCCCS(=O)(=O)C)COC1=CC=C(C=C1)[C@H](CC)C#CC Chemical compound CC1=C2C=3C=C(C=CC3CCC2=CC(=C1)OCCCS(=O)(=O)C)COC1=CC=C(C=C1)[C@H](CC)C#CC HLILQLUWVHRVRM-RUZDIDTESA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 claims 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- MLBYLEUJXUBIJJ-UHFFFAOYSA-N pent-4-ynoic acid Chemical compound OC(=O)CCC#C MLBYLEUJXUBIJJ-UHFFFAOYSA-N 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- NIDHFQDUBOVBKZ-NSCUHMNNSA-N trans-hex-4-enoic acid Chemical compound C\C=C\CCC(O)=O NIDHFQDUBOVBKZ-NSCUHMNNSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130022038 | 2013-02-28 | ||
| KR10-2013-0022038 | 2013-02-28 | ||
| KR10-2013-0109840 | 2013-09-12 | ||
| KR20130109840 | 2013-09-12 | ||
| PCT/KR2014/001686 WO2014133361A1 (ko) | 2013-02-28 | 2014-02-28 | 삼환식 화합물 및 이의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513135A JP2016513135A (ja) | 2016-05-12 |
| JP2016513135A5 true JP2016513135A5 (cg-RX-API-DMAC7.html) | 2017-02-16 |
| JP6387023B2 JP6387023B2 (ja) | 2018-09-05 |
Family
ID=51428545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560105A Expired - Fee Related JP6387023B2 (ja) | 2013-02-28 | 2014-02-28 | 三環式化合物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9643946B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2963027B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6387023B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101735787B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN108017603B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014221489B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2900348C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2709195T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014133361A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3068788A1 (en) | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| US10301217B2 (en) * | 2014-12-23 | 2019-05-28 | Boral Ip Holdings (Australia) Pty Limited | Rapid setting material for improved processing and performance of carbonating metal silicate cement |
| CA3006683A1 (en) | 2015-12-22 | 2017-06-29 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
| KR102538719B1 (ko) | 2016-12-08 | 2023-06-01 | 메르크 파텐트 게엠베하 | 중합가능한 화합물 및 액정 디스플레이에서 이의 용도 |
| CN108218824B (zh) * | 2016-12-09 | 2020-06-26 | 中国科学院大连化学物理研究所 | 二苯基并[b，d]氧杂环庚烷化合物及其制备和应用 |
| WO2018138030A1 (en) * | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10793530B2 (en) | 2017-01-26 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10919859B2 (en) | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110198928B (zh) | 2017-01-26 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途 |
| JP7049353B2 (ja) | 2017-02-08 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN111655678B (zh) * | 2018-01-05 | 2023-08-22 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| JP6626524B2 (ja) | 2018-03-29 | 2019-12-25 | 日本碍子株式会社 | 電気加熱型触媒用担体 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN110105193B (zh) * | 2019-05-31 | 2022-03-22 | 杭州科耀医药科技有限公司 | 一种2-卤-5-溴苯甲酸的合成方法 |
| WO2025082467A1 (zh) * | 2023-10-19 | 2025-04-24 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN117510323B (zh) * | 2024-01-08 | 2024-04-05 | 成都泰莱康科技有限公司 | 一种Ramage Linker中间体的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1523015A (zh) | 1997-02-10 | 2004-08-25 | �Ʒ� | 2-氨基-6-(2-取代的-4-苯氧基)取代的吡啶类化合物 |
| AU7950100A (en) | 1999-10-22 | 2001-05-08 | Takeda Chemical Industries Ltd. | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| CA2505322A1 (en) * | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| CN1735408A (zh) * | 2002-11-08 | 2006-02-15 | 武田药品工业株式会社 | 受体机能调节剂 |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| US7834013B2 (en) * | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
| JP4074616B2 (ja) * | 2003-12-25 | 2008-04-09 | 武田薬品工業株式会社 | ３−（４−ベンジルオキシフェニル）プロパン酸誘導体 |
| AU2004309271A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| CA2558585C (en) * | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| EP1916234B1 (en) * | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| MX2008011615A (es) * | 2006-03-14 | 2008-09-22 | Amgen Inc | Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos. |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| RS53230B (sr) | 2006-06-27 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora |
| EP2064193A1 (en) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
| AU2008241490B2 (en) * | 2007-04-16 | 2011-07-21 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators |
| PE20090595A1 (es) | 2007-08-15 | 2009-06-06 | Glaxo Group Ltd | Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1 |
| EP2215068B1 (en) * | 2007-10-29 | 2012-06-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN102421739A (zh) * | 2009-04-22 | 2012-04-18 | 安斯泰来制药株式会社 | 羧酸化合物 |
| WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
| TW201221505A (en) * | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
-
2014
- 2014-02-28 EP EP14756272.2A patent/EP2963027B1/en active Active
- 2014-02-28 US US14/771,049 patent/US9643946B2/en not_active Expired - Fee Related
- 2014-02-28 KR KR1020140024555A patent/KR101735787B1/ko not_active Expired - Fee Related
- 2014-02-28 CA CA2900348A patent/CA2900348C/en active Active
- 2014-02-28 CN CN201711200963.6A patent/CN108017603B/zh not_active Expired - Fee Related
- 2014-02-28 WO PCT/KR2014/001686 patent/WO2014133361A1/ko not_active Ceased
- 2014-02-28 AU AU2014221489A patent/AU2014221489B2/en not_active Ceased
- 2014-02-28 CN CN201480011110.6A patent/CN105209448B/zh not_active Expired - Fee Related
- 2014-02-28 JP JP2015560105A patent/JP6387023B2/ja not_active Expired - Fee Related
- 2014-02-28 ES ES14756272T patent/ES2709195T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513135A5 (cg-RX-API-DMAC7.html) | ||
| Chen et al. | Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-aryl-2-benzoyl-pyridines as potential anticancer agents | |
| JP2013510124A5 (cg-RX-API-DMAC7.html) | ||
| JP6325078B2 (ja) | ヘテロ環式化合物およびその使用 | |
| RU2013142012A (ru) | 1,4 тиазепины/сульфоны в качестве ингибиторов васе1 и(или) васе2 | |
| PE20151539A1 (es) | Nuevos derivados de pirazol | |
| JP2013529611A5 (cg-RX-API-DMAC7.html) | ||
| RU2672910C9 (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
| JP2016172739A5 (cg-RX-API-DMAC7.html) | ||
| HRP20161482T1 (hr) | Derivati tienopiridona korisni kao aktivatori ampk | |
| EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
| BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
| NZ592890A (en) | Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor | |
| WO2012066578A2 (en) | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof | |
| JP2016527296A (ja) | Ｃｆｔｒモジュレーターとしてのチエノ［２，３−ｃ］ピラン | |
| NZ605528A (en) | Ip receptor agonist heterocyclic compounds | |
| PE20141540A1 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| ES2495965T3 (es) | Uso de derivados 2,5-dihidroxibencénicos para el tratamiento de enfermedades oculares | |
| RU2013143746A (ru) | 1,4-оксазепины в качестве ингибиторов васе1 и(или) васе2 | |
| JP2015518008A5 (cg-RX-API-DMAC7.html) | ||
| JP2017536409A5 (cg-RX-API-DMAC7.html) | ||
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| RU2013116801A (ru) | Ингибиторы notum пектинацетилэстеразы и способы их применения | |
| EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
| JP2013518904A5 (cg-RX-API-DMAC7.html) |